Author

Curtis Freedland

Observed names: C Freedland, C.P. Freedland, Curtis P. Freedland

Institution: Advanced Research Institute

Observed institutions: Wayne State University, Harper University Hospital, Advanced Research Institute, University of California Davis Medical Center

OpenAlex ID: A5000137792

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

2020 · Stephen A. Harrison, Vincent Wai-Sun Wong, et al. · Journal of Hepatology · 493

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134

Microbial Contamination of Continuous Drip Feedings

1989 · Curtis P. Freedland, Robert D. Roller, et al. · Journal of Parenteral and Enteral Nutrition · 89

Microbial contamination of continuous drip feedings

1987 · C.P. Freedland, R.D. Roller, et al. · American Journal of Infection Control · 6

Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells

1990 · Sarabjit S. Neelam, Alvise Bernabei, et al. · Investigational New Drugs · 5

OS-059 Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2b trial (VANTAGE): 28-week interim results

2025 · Michael Heneghan, Mitchell Shiffman, et al. · Journal of Hepatology · 4

Exploring the role of ileal bile acid transporter inhibitors, like volixibat, in the regulation of IL-31 and serum bile acids in patients with primary biliary cholangitis: Preliminary results from the VANTAGE trial

2026 · J Trebicka, A Bonder, et al. · Zeitschrift für Gastroenterologie

Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: Data from VANTAGE

2026 · J Trebicka, K V Kowdley, et al. · Zeitschrift für Gastroenterologie

Tu2024 VOLIXIBAT LEADS TO IMPROVEMENTS IN FATIGUE AND SLEEP FOR ADULTS WITH PRIMARY BILIARY CHOLANGITIS: DATA FROM VANTAGE

2026 · Mitchell L. Shiffman, Debra Weinstein, et al. · Gastroenterology

Tu2023 EXPLORING THE ROLE OF VOLIXIBAT, AN ILEAL BILE ACID TRANSPORTER INHIBITOR, IN THE REGULATION OF IL-31 AND SERUM BILE ACIDS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: PRELIMINARY RESULTS FROM THE VANTAGE TRIAL

2026 · Mitchell L. Shiffman, Alan Bonder, et al. · Gastrointestinal Endoscopy

Tu2023 EXPLORING THE ROLE OF VOLIXIBAT, AN ILEAL BILE ACID TRANSPORTER INHIBITOR, IN THE REGULATION OF IL-31 AND SERUM BILE ACIDS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: PRELIMINARY RESULTS FROM THE VANTAGE TRIAL

2026 · Mitchell L. Shiffman, Alan Bonder, et al. · Gastroenterology

Tu2024 VOLIXIBAT LEADS TO IMPROVEMENTS IN FATIGUE AND SLEEP FOR ADULTS WITH PRIMARY BILIARY CHOLANGITIS: DATA FROM VANTAGE

2026 · Mitchell L. Shiffman, Debra Weinstein, et al. · Gastrointestinal Endoscopy

147 - Volixibat for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis: an Adaptive, Randomized, Placebocontrolled Phase 2b Trial (vantage): 28-week Interim Results

2026 · Michael Heneghan, Mitchell Shiffman, et al. · Gastroenterología y Hepatología

Volixibat zur Behandlung des cholestatischen Pruritus bei primär biliärer Cholangitis: Zwischenergebnisse der adaptiven, randomisierten, placebokontrollierten Phase-IIb-Studie (VANTAGE)

2025 · J Trebicka, K V Kowdley, et al. · Zeitschrift für Gastroenterologie

784: Volixibat for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis: an Adaptive, Randomized, Placebo-controlled Phase 2b Trial (vantage): Interim Results

2025 · Kris V. Kowdley, Mitchell L. Shiffman, et al. · Gastroenterology

Works count: 15

Citation count: 731

H-index: 5

I10-index: 3